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Abstract
Background: Tuberculosis (TB) is the most common opportunistic infection and the leading cause of death in
HIV-positive people worldwide. Diagnosing TB is difficult, and is more challenging in resource-scarce settings where
culture-based diagnostic methods rely on poorly sensitive smear microscopy by Ziehl-Neelsen stain (ZN).
Methods: We performed a cross-sectional study examining the diagnostic utility of Microscopic Observation Drug
Susceptibility liquid culture (MODS) versus traditional Ziehl-Neelsen staining (ZN) and Lowenstein Jensen culture
(LJ) of pulmonary tuberculosis (TB) and multidrug-resistant tuberculosis (MDRTB) in HIV-infected patients in Bolivia.
For sputum scarce individuals we assessed the value of the string test and induced sputum for TB diagnosis. The
presence of Mycobacterium tuberculosis (Mtb) in the sputum of 107 HIV-positive patients was evaluated by ZN, LJ,
and MODS. Gastric secretion samples obtained by the string test were evaluated by MODS in 102 patients.
Results: The TB-HIV co-infection rate of HIV patients with respiratory symptoms by sputum sample was 45 % (48/107);
46/48 (96 %) were positive by MODS, 38/48 (79 %) by LJ, and 30/48 (63 %) by ZN. The rate of MDRTB was 9 % (4/48).
Median time to positive culture was 10 days by MODS versus 34 days by LJ (p < 0.0001). In smear-negative patients,
MODS detected TB in 17/18 patients, compared to 11/18 by LJ (94.4 % vs 61.0 %, p = 0.03 %). In patients unable to
produce a sputum sample without induction, the string test cultured by MODS yielded Mtb in of 9/11 (82 %) TB
positive patients compared to 11/11 (100 %) with induced sputum. Of the 10 patients unable to produce a sputum
sample, 4 were TB-positive by string test.
Conclusion: MODS was faster and had a higher Mtb detection yield compared to LJ, with a greater difference in yield
between the two in smear-negative patients. The string test is a valuable diagnostic technique for HIV sputum-scarce
or sputum-absent patients, and should be considered as an alternative test to induced sputum to obtain sample for
Mtb in resource-limited settings. Nine percent of our TB+ patients had MDRTB, which reinforces the need for rapid
detection with direct drug susceptibility testing in HIV patients in Bolivia.
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Background
Tuberculosis (TB) is the most common opportunistic in-
fection and the leading cause of death in HIV-positive
people worldwide [1]. Diagnosing TB is difficult, and is
more challenging in resource-scarce settings where those
without timely culture-based diagnostic methods rely on
poorly sensitive smear microscopy using Ziehl-Neelsen
stain (ZN) [1–3].
Co-infection with HIV and TB affects the diagnosis of
TB, as well as the morbidity, and mortality of patients in a
multi-faceted manner. TB diagnosis in HIV is complicated
by pauci-bacillary infection and atypical presentations of
disease [4]. TB has been shown to increase HIV viral
replication and may accelerate HIV progression [5] and
increase mortality [6–8].
In the HIV population, smear microscopy detects only
35-61 % of culture-positive pulmonary TB infections [7, 9,
10], compared to 50-80 % in HIV-negative patients [3].
Given the increased incidence and mortality of smear-
negative TB in HIV patients, culture is recommended [2,
3], but not widely used. When performed, culture improves
detection of active TB; however, commonly used solid cul-
ture methods, including Lowenstein Jensen culture (LJ),
may take 6–8 weeks, and lack concurrent antibiotic sensi-
tivity data [3, 11, 12]. Ultra rapid test GeneXpert is cur-
rently recommended by the WHO as a first line TB test in
the HIV population [13], but it is limited by lower sensitiv-
ity in smear negative patients and cost. At $10/cartridge
and $17,000/machine, cost remains a barrier to widespread
implementation, therefore alternative methods for rapid TB
diagnosis in HIV patients are needed in resource limited
areas [14–16].
TB-HIV co-infection and Multidrug-resistant Tuberculosis
(MDRTB) in Bolivia
Bolivia has the highest rate of active TB in South America,
and one of the highest in the world, with an estimated
prevalence of 196 in 100,000 [1]. Although only 11,421
total cases of HIV were reported in 2014, it was estimated
that 15,000 persons were living with HIV in Bolivia, and
1000 deaths were attributed to AIDS [17]. Despite the
prevalence of TB infection in Bolivia, WHO reported only
170 total patients with HIV-TB co-infection in 2013 [1].
Worldwide prevalence of MDRTB is increasing, and
remains underdiagnosed [1]. It is estimated that only
7 % of the 500,000 people with MDRTB are recognized
as MDR, which may lead to increased treatment failure
and jeopardize the success of TB control efforts [1]. The
WHO reported 1.2 % of newly diagnosed TB cases in
Bolivia in 2013 were MDR [1]. In parts of the world
where either MODS or GeneXpert are available, the
diagnosis of either MDRTB or Rifampicin-resistant TB
is made when the test returns positive for TB [13, 18,
19]. Currently, in Bolivia, however, diagnosis of MDRTB
relies on LJ followed by further antimicrobial sensitivity
testing, which can delay drug susceptibility results for
weeks after initial diagnosis [20].
Microscopic Observation Drug Susceptibility Culture
(MODS)
The MODS assay is a low-cost, liquid culture used for the
diagnosis of TB and direct drug susceptibility testing which
uses commonly available laboratory materials in order to
permit its application in resource-limited settings [18, 19].
MODS is based on the principles that Mtb grows faster in
liquid than in solid medium and characteristic cording for-
mation that is specific for Mtb is microscopically observed
early in liquid medium [18]. The incorporation of Rifampi-
cin and Isoniazid during the initial stage of the culture
permits concurrent and direct drug-susceptibility testing,
obviating the need for subculture sensitivity testing [18, 19].
Currently MODS costs $3 per test, and the recent develop-
ment of a low-cost inverted microscope, automated plate
readers, and a standardized TB MODS KIT will streamline
the cultivation process, conserve labor hours preparing ne-
cessary reagents, and may further decrease costs [21, 22].
In a policy statement in 2011, the WHO approved MODS
for drug susceptibility screening for MDRTB [23].
Scarce sputum production in HIV patients
Obtaining an adequate sputum sample from patients with
scarce sputum production is challenging in HIV-positive
patients. Lack of productive cough in AIDS patients corre-
lates poorly with the presence of pulmonary TB [24]. The
most widely used option for sample obtainment is sputum
induction. The string test, originally demonstrated for the
retrieval of enteropathogens from the upper gastrointes-
tinal tract [25, 26], has been shown to be a safe method of
sample collection for the diagnosis of pulmonary TB in
HIV patients [24].
Our study examines the diagnostic utility of Micro-
scopic Observation Drug Susceptibility liquid culture
(MODS) versus traditional Ziehl-Neelsen staining (ZN)
and Lowenstein Jensen culture (LJ) of pulmonary tubercu-
losis (TB) and multidrug-resistant tuberculosis (MDRTB)
in HIV-infected patients in Bolivia. For sputum scarce in-
dividuals we assessed the value of the string test and in-
duced sputum for TB diagnosis.
Methods
Study patients and setting
This was a prospective and consecutive cross-sectional
study conducted from February 2010 through August
2011 in Cochabamba, Bolivia, a city identified as an
endemic TB region with an incidence of smear-positive
pulmonary TB of 41.4 per 100,000 in 2011 [2].
All study participants were HIV-positive patients, con-
firmed by Western blot, with respiratory symptoms such
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as cough or dyspnea. Constitutional symptoms and risk
factors for tuberculosis were noted on further evaluation
but not assessed for study inclusion. Hospitalized subjects
were evaluated upon admission to the infectious diseases
ward of the Universidad San Simon, the public hospital in
Cochabamba. Ambulatory subjects were evaluated upon
presentation to the clinic with respiratory symptoms. Sub-
jects were excluded if they were under 18 years of age, un-
willing or unable to provide informed consent or actively
receiving tuberculosis therapy for more than seven days.
Study protocol and consent forms were approved by the
institutional review boards of Universidad Peruana Caye-
tano Heredia, Asociación Benefica PRISMA, and Johns
Hopkins Bloomberg School of Public Health.
Sample collection
Participants were asked to submit three early-morning spu-
tum samples and a gastric secretion sample by the string
test. The first sample was divided into three aliquots to be
processed by ZN, LJ, and MODS Two additional sputum
samples were sent for ZN smear. Patients unable to pro-
duce adequate sputum (defined as minimum volume of
1 ml/culture sample of what macroscopically appeared to
be sputum) were induced by a nebulizer with 3-5 % saline
solution for up to three 5-min-intervals. Later in the study,
all patients were asked to submit both a spontaneous
sample and an induced sputum sample for comparison. Pa-
tients able to produce sputum spontaneously were consid-
ered “sputum productive.” Patients unable to produce a
spontaneous sputum sample but with an adequate induced
sputum sample were considered “sputum-scarce.” Patients
unable to produce a sputum sample despite sputum induc-
tion were considered “sputum-absent.” Those willing to
take part in the string test swallowed a gelatin capsule
hand-packed with a 90 cm string after 8 hours of fasting.
The trailing end of the string was attached to the patients’
cheek when swallowed. After one hour of intragastric time
[27] the string was retrieved and the intragastric contents
on the string were cultured by MODS as described below.
If consented but unable to submit at least one sample
(either sputum or string), they were excluded from study.
Laboratory methods
String test samples were processed according to proto-
cols described in previous publications25. Sputum and
gastric samples were stored at 4 °C and were cultured as
soon as possible after collection (Median 3.5 days, IQR
1–6). All specimens were decontaminated by the stand-
ard NALC-NaOH-Na citrate method [28]. MODS was
performed as described in previous publications [18, 19]
and cultures were examined every other day (excluding
weekends) until day 30. LJ cultures were performed ac-
cording to the protocol set by the National TB Program
of Bolivia, and samples were inoculated at 37 °C and
examined twice weekly until day 60. Rifampin and Isoniazid
susceptibilities in this study were assessed through MODS
alone.
Statistical analysis
Data were analyzed using STATA 10, PRISM, and Excel
software. Comparisons of categorical data were performed
with either the Chi-squared test or Fisher’s exact test; com-
parisons of continuous data were performed with either t-
test or Wilcoxon rank sum test. Comparisons of diagnostic
yield between the different methods were assessed using
McNemar’s Chi-square test or McNemar’s exact test.
As all patients had respiratory symptoms, a patient with
a sputum or string test sample that was culture positive by
Lowenstein Jensen or MODS was considered TB positive
(“definite TB” according to 2012 NIH Consensus guide-
lines). As our study is evaluating MODS, with a known
higher sensitivity than the reference test, this composite
culture positivity was used as the reference standard to
evaluate each test. As a result, our results reflect diagnos-
tic yield of each detection method; we are unable to com-
ment on the true sensitivity or specificity of each method.
Standard anti-tuberculosis treatment was administered to
patients with a positive result by any of the above diagnos-
tic methods by the attending on service after communica-
tion of the positive results. Although this study was not
initially designed to determine mortality, we did note if
patients died by the time that his or her culture results
were available. We defined mortality as death within
60 days of sample collection, the longest time period in
which we would have contacted a patient with culture
results.
Results
Samples obtained and patient characteristics
Of the 134 patients enrolled in the study, 107 (79.8 %)
subjects submitted sputa that were evaluated by ZN, LJ,
and MODS. Additionally, 24 of these 107 patients (22.4 %)
submitted both induced and spontaneous sputum sample
for comparison. Of the 107 patients who submitted spu-
tum, 92 (85.9 %) also submitted a string sample. 10 pa-
tients were unable to produce sputum but submitted a
string test. Of those who submitted a string sample (n =
102), the patients were grouped into “sputum productive”
(68.6 %), “sputum scarce” (21.5 %), or “sputum ab-
sent”(9.8 %), based on their degree of sputum production
(See Fig.1).
The median age of the patients was 32 years (IQR 27–
43). 101/107 patients (94.4 %) reported cough; median
duration of cough prior to presentation was 20.5 days
(IQR 7–60). 25/107 patients reported hemoptysis (23.3 %).
65/107 patients reported shortness of breath (60.7 %). 81/
107 (75.7 %) of patients reported fever, 68/107 (63.5 %) of
patients reported night sweats. 56/107 (52.3 %) reported
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both fevers and night sweats. The median CD4 count for
all 107 patients was 98 cells/mm3; for hospitalized patients
was 76.5; for ambulatory patients was 192 (Table 1). Only
28 of the 107 patients (26.1 %) were on ARVs at the time
of sample collection. Of the TB+ patients, 12/48 (25.0 %)
were on ARVs.
Rates of TB and Associated Mortality of TB+ pts
Of the 107 patients, 44.9 % (48/107) were Mtb culture
positive by MODS or LJ culture of the sputum or string
test sample and were considered TB+. The rates of TB
in hospitalized patients (n = 35, 46.1 %) versus ambula-
tory (n = 13, 41.9 %) were similar. The mortality rate of
all TB+ patients was 45.8 % (22/48) (see Table 1). Of
those TB+ sensitive to both rifampin and isoniazid,
mortality was 35.0 % (14/40); of those TB+ with resist-
ance to one or more anti-TB drugs, mortality was 75 %
(6/8); p = 0.08.
Of the 22 TB+ patients that died during the study, the
median CD4 count was 59 (IQR 29–132.5), compared to
174 (IQR 52–257) in surviving TB+ patients (n = 26).
Between these two groups, their median duration of
symptoms prior to presentation was 21 days in deceased
patients (IQR 4.75-97.5) versus 30 days in surviving pa-
tients (IQR 9.25-97.5). The rates of antiretroviral therapy
at the time of enrollment in these two groups were simi-
lar (5/22 of deceased patients, 6/26 of surviving patients,
p = 0.62).
Mtb Detection and Time to Positivity
MODS detected Mtb in 46/48 TB+ patients with a diagnos-
tic yield of 95.8 % (95 % CI, 85.7-99.5), and detected Mtb in
significantly more patients than LJ (38/48, 79.2 %, p =
0.022) and ZN (30/48, 62.5 %, p < 0.001). In the ambulatory
patients, MODS detected Mtb in 12/13 TB+ patients
(92.3 %) versus LJ in 7/13 (53.8 %), p = 0.06, and the
Fig. 1 Recruitment of patients, samples obtained, and resulting groups of patients for sample analysis. 134 patients were enrolled in the study. 7
patients were unable to produce at least one sample (either string or sputum) and were excluded. 5 patients were excluded as their cultures
were contaminated. 5 samples had long delays in processing by lab (>12 days); these patients were excluded. 107 subjects submitted a sputum
sample sufficient for evaluation by ZN, LJ, and MODS that that were included in the analysis. Additionally, 24 of these patients submitted both
induced and spontaneous sputum sample for comparison. Of the 107 patients who submitted an adequate sputum sample, 92 also submitted a
string sample. 10 additional patients submitted string sample but did not submit sputum sample. Of these102 patients that submitted a string
test sample, 70 patients (68.6 %) were able to produce sputum spontaneously (“sputum productive”). 22 patients (21.5 %) were only able to
produce a sputum sample after induction (“sputum-scarce”). Ten patients (9.8 %) were unable to produce any sputum (“sputum-absent”). While
we note the results of these 10 string samples, these ten patients were not included in our larger analysis of TB diagnostic methods as there was
no sputum for comparison
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detection yield of LJ was similar to that of ZN (53.8 % vs
61.5 %, p = 1.00). See Table 2.
Thirty-seven percent (18/48) of TB+ patients were
smear-negative. In the smear-negative group, MODS de-
tected TB in 17/18 patients, significantly more detected
than the 11/18 by LJ (94.4 % vs 61.0 %, p = 0.03 %). In
the smear-positive group (30/48) the difference was not
significant (MODS 96.6 % and LJ 90.0 %, p = 0.63). See
Table 2.
The median time to sputum culture positivity was sig-
nificantly shorter for MODS than for LJ (10 and 34 days,
p < 0.0001). Within MODS, smear status significantly af-
fected time to positivity (median 8 versus 13 days in
smear-positive and negative samples, p < 0.0001). This
difference was not seen in LJ by smear status. See Fig. 2.
The string test: performance in sputum-productive,
sputum-scarce and sputum-absent patients
Sputum-scarce patients had a lower median CD4 count
than sputum productive patients (55 versus 122; p = 0.021).
3 of 22 (13.6 %) sputum scarce patients were on ARVs at
the time of enrollment compared to 21 of 90 (23.3 %) of
sputum productive patients. The rate of TB+ in the
sputum-scarce group was 50 % (11/22), compared to 40 %
(28/70) in the sputum-productive patients (p = 0.41). Of
those TB+, the sputum-scarce group had a higher mortality
rate (8/11, 72.7 %) than the sputum-productive group (10/
28 35.7 %), p = 0.041. See Table 3.
Cultures of string test sample and sputum were com-
pared by MODS. In the sputum-productive group (n =
70), of the 28 TB+ patients, culture of the string test
yielded Mtb in 18/28 (64.2 %) patients compared to 27/
28 (96.4 %) with sputum (p = 0.012). In the sputum-
scarce group (n = 22), of the 11 TB+ patients, the string
test yielded Mtb in 9/11 (81.8 %) patients compared to
11/11 (100 %) with induced sputum (p = 0.50). Ten pa-
tients with a dry cough were “sputum absent”, and were
only able to submit a string sample; culture of the string
test yielded Mtb in 4/10 of these patients. See Table 3.
In the sputum-productive group, time to positivity for
sputum cultured by MODS was significantly faster than
string test cultured by MODS (median 9 vs 15 days, p =
Table 1 Patient Characteristics: Median ages and CD4 counts, rates of TB positivity, and associated mortality of all TB+ patients that
submitted sputum for comparison, stratified by hospitalized and ambulatory groups
n Median Age (IQR) Median CD4 count (IQR) TB+ (%) Mortality of TB+
All patients 107 32 (27–43) 98 (33–249) 48/107 (44.9 %) 22/48 (45.8 %)
Hospitalized patients 76 32 (27–46)* 76.5 (29.0-162)** 35/76 (46.1 %)*** 18/35 (51.4 %)****
Ambulatory patients 31 32 (28–42)* 192 (64–339)** 13/31 (41.9 %)*** 4/13 (30.7 %)****
107 patients were included in analysis. Median age of all patients as well as those hospitalized vs ambulatory was 32. Median CD4 count for all patients was 98.
Median CD4 count of hospitalized patients was 76 and median CD4 for ambulatory patients was 192. Rates of TB positivity (TB+), defined as a patient with a
sputum or gastric string sample that was culture positive by MODS or Lowenstein Jensen, was 44.9 % in all patients, 46.1 % in hospitalized patients, and 41.9 % in
ambulatory patients. Of those who were TB+, the mortality rate overall was 45.8 %. The mortality rate for hospitalized TB+ patients was 51.4 % and for
ambulatory TB+ patients, it was 30.7 %
n number of patients in each group. Medians are displayed in year. IQR Interquartile range
*The difference between the median age of hospitalized versus ambulatory patients was not statistically significant (p = 0.87)
**The difference between the median CD4 count of hospitalized versus ambulatory (76.5 vs 192) was statistically significant (p = 0.01)
**The difference between the rates of TB of hospitalized vs ambulatory patients (46.1 % vs 41.9 %) was not statistically significant (p = 0.70)
***The difference between the mortality of the TB+ hospitalized patients vs mortality of TB+ ambulatory patients (51.4 % vs 30.7 %) was not statistically
significant (p = 0.08)
Table 2 Comparison of diagnostic methods for the detection of Mtb in hospitalized versus ambulatory and in smear-positive versus
smear-negative patients
A. All patients Hospitalized patients Ambulatory patients
TB+ (n = 48) Diagnostic yield (95 % CI) TB+ (n = 35) Diagnostic yield (95 % CI) TB+ (n = 13) Diagnostic yield (95 % CI)
MODS 46 95.8 % (85.7-99.5) 34 97.1 % (85.1-99.9) 12 92.3 % (64.0-99.8)
LJ 38 79.2 % (65.0-89.5) 31 88.6 % (73.3-96.8) 7 53.8 % (25.1-80.8)
ZN 30 62.5 % (47.3-76.0) 22 62.9 % (44.9-78.5) 8 61.5 % (31.6-86.1)
B. All patients Smear-positive Smear-negative
TB+ (n = 48) Diagnostic yield (95 % CI) TB+ (n = 30) Diagnostic yield (95 % CI) TB+ (n = 18) Diagnostic yield (95 % CI)
MODS 46 95.8 % (85.7-99.5) 29 96.6 % (82.8-99.9) 17 94.4 % (72.7-99.9)
LJ 38 79.2 % (65.0-89.5) 27 90.0 % (73.4-97.9) 11 61.0 % (35.7-82.7)
TB+ was defined as any patient with sputum or gastric sample that yielded a positive culture result by LJ or MODS. As the reference standard is a composite from
all tests that are being evaluated, we can only comment on diagnostic yield rather than sensitivity and specificity. Panel A: Comparison of diagnostic yield of
MODS versus LJ and ZN in all patients, hospitalized patients, and ambulatory patients who were TB positive. Panel B: Subgroup comparison of the diagnostic yield
of MODS versus LJ in culture positive patients, sub-grouped into all patients, smear positive patients, and smear negative patients
n number of patients in each group; CI confidence interval; TB + samples tested positive for Mtb by each respective method (MODS, LJ, or ZN)
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0.006). In the sputum-scarce group, time to positivity of
induced sputum was similar to that of string test (me-
dian 11 vs 14 days, p = 0.31). The string test samples
were not neutralized until just prior to culture, and this
along with the processing delay may have negatively
affected both diagnostic yield and time to positivity.
See Fig. 2.
Detection of Mtb in induced sputum versus spontaneous
sputum using MODS culture
24 patients submitted both spontaneous and induced
sputum. In this group, 14 patients were TB positive by at
least one of the samples obtained. Of these 14 patients,
MODS detected TB in 92.8 % (13/14) of the induced
sputum samples vs 78.6 % (11/14) of the spontaneous
Fig. 2 Cumulative percentages of the time to culture positivity for culture-positive samples according to culture method (a), according to smear status
of sputa (b and c), and according to sample type in sputum-productive and sputum-scarce patients (d and e). A. Median time to sputum culture
positivity cultured by MODS vs LJ (10 days vs 34 days, p <0.0001). b. Within MODS culture of sputa, effect of smear-positive vs smear-negative on
time to culture positivity (median 8 vs 13 days, p <0.001). c. Within LJ of sputa, effect of smear-positive vs smear-negative on time to culture positivity
(median 30 vs 40 days, p = 0.1367) d. Within the sputum-productive cohort, time to culture positivity of MODS sputum vs MODS string test (median 9
vs 13 days, p = 0.0058). e Within the sputum-scarce cohort, time to culture positivity of MODS sputum vs MODS string test (median 11 vs 14 days,
p = 0.3159). String samples were not neutralized prior to storage and this may have affected both diagnostic yield and time to positivity. Median
times to processing with interquartile ranges for each group of samples are below: All MODS Sputum Samples: Median 3 days (IQR 1–5). MODS
Smear-positive Sputum Samples: Median 4 days (IQR 2–5). MODS Smear-negative Sputum samples: Median 2 days (IQR 2–4.75). LJ Sputum samples:
Median 5 days (IQR 2–6). All MODS String Samples: Median 3 days (IQR 1–5). MODS Sputum-Productive Sputum Samples: Median 3 days (IQR 2–5).
MODS Sputum-Productive String Samples (Median 3 days (IQR 2–5). MODS Sputum-Scarce Sputum Samples: Median 4 days (IQR 2–6). MODS
Sputum-Scarce String Samples: Median 4 days (IQR 2–6)
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sputum samples (p = 0.63). The median time to positivity
for induced versus spontaneous sputum was not signifi-
cantly different (11 vs 9 days, p = 0.30). See Fig. 2.
Rates of MDRTB in TB-HIV co-infection
The rate of both Rifampin and Isoniazid resistance
(MDRTB) in our study was 9.0 % (4/46). Rates of resist-
ance to Rifampin alone was 4.0 % (2/46) and to Isoniazid
alone was 4.0 % (2/46), thus a total of 17.0 % (8/46) of
patients were resistant to at least one of these two medi-
cations. Resistance is determined concurrently with ini-
tial positive MODS culture, so time to resistance
parallels that of time to positivity as described above.
Discussion
The data from our study stresses the need for a rapid TB
diagnostic test in HIV patients in Bolivia. The rate of TB in
HIV patients with respiratory symptoms was very high
(45 %), and almost half (46 %) of these patients died within
60 days. Furthermore, the rate of TB-HIV co-infection in
our study alone over a 1.5 year period (n = 48) does not cor-
relate well with the rate of HIV-TB co-infection in all of
Bolivia reported in 2013 (n = 170) [1]; this data raises con-
cern that this is a problem of greater magnitude than is cur-
rently appreciated. Even more alarming is the prevalence of
MDRTB in our population of HIV patients (9 %), which is
much higher than the reported MDRTB rates in Bolivia;
and that 75 % of those with resistance to one or more drugs
died during the duration of our study. A similar study by
Kawai et al. in Peru showed that MDRTB-HIV co-infection
had a mortality rate above 50 % within two months and
was associated with a high rate of continued infectiousness
[29]. Current methods of resistance testing in Bolivia can
take weeks beyond positive solid culture results, risking
significant delays of appropriate treatment. These data
strongly reinforce the need for the implementation of a
rapid TB diagnostic method with direct drug susceptibility
testing in the HIV population in Bolivia. Additionally, the
discrepancy between the rates of resistance found in our
study compared to previous reports, calls for a dedicated
study of antibiotic resistance in Bolivia in HIV patients.
Given the increased rates of MDRTB in HIV, the risk of
nosocomial spread, and the high mortality associated with
this co-infection, if these rates of MDRTB are confirmed in
future studies, MDRTB in Bolivia could quickly become a
greater threat to public health.
Our study demonstrates that MODS is a valuable
method for rapid diagnosis of TB in the HIV population.
In this study, the detection yield of MODS was superior
to LJ. Additionally, consistent with prior studies based in
centralized MODS laboratories, Mtb was observed in
MODS in less than one-third of the time of growth in LJ
[18, 19, 23]. MODS’ increased diagnostic yield was most
profound in the smear-negative HIV patients, a vulner-
able group at highest risk for missed or delayed diagno-
sis. Although smear-negative sputum samples cultured
by MODS grew later than MODS smear-positive sam-
ples, smear-negative samples by MODS still grew signifi-
cantly faster than those by LJ.
Our results emphasize the utility of MODS in the am-
bulatory population. MODS detected almost 30 % more
disease than LJ in this population, and LJ did not identify
any more disease than ZN alone, supporting a use for
MODS in patients with milder presentations.
As this study highlights the need for widespread im-
plementation of a rapid, sensitive TB diagnostic method
Table 3 String Test sub-analysis: Patient characteristics and comparison of diagnostic methods in sputum productive, sputum scarce
and sputum absent patient subgroups
Patient Characteristics (n = 102) Sputum-productive (n = 70) Sputum-scarce (n = 22) Sputum-absent (n = 10)
Median age (years) 32 30.5 36
CD4 count 122 (IQR 45–271) 55 (IQR 23–86) 221 (IQR 133–486)
Rate of TB+ 28/70 (40 %) 11/22 (50 %) 4/10 (40 %)
Mortality of TB+ 10/28 (35.7 %) 8/11 (72.7 %) 0/4 (0 %)
Test +Mtb (n = 28) Diagnostic yield (95 % CI) +Mtb (n = 11) Diagnostic yield (95 % CI) +Mtb (n = 4) Diagnostic yield
String test MODS 18 64.2 % (44.7-81.4) 9 81.8 % (48.9-97.7) 4 a
Sputum MODS 27 96.4 % (81.7-99.9) 11 100 % (71.5-100) a a
Sputum LJ 21 75.0 % (55.1-89.3) 10 90.9 % (58.7-99.8) a a
Sputum ZN 17 60.7 % (40.6-78.5) 7 63.6 % (30.8-89.1) a a
TB positive was defined as any patient with sputum or gastric sample with a positive culture result from sputum or string test by LJ or MODS. This composite
positivity was used as the reference standard to determine diagnostic yield. The patients that submitted a string test (n = 102) were divided into three groups
based on degree of sputum productivity. Sputum-productive patients (n = 70, 68.6 %) were able to produce spontaneous sputum. Sputum-scarce patients (n = 22,
21.5 %) required sputum induction to produce sample. Sputum-absent patients (n = 10, 9.8 %) were unable to produce sputum despite induction and only
submitted a string sample. Of the sputum absent patients, 4 patients were positive for Mtb by string test, but there are no samples for comparison since they
were unable to produce sputum. The string test samples were not neutralized prior to culture and this may have affected diagnostic yield
n number of patients in group; IQR interquartile range; CI confidence interval
a We are unable to provide these numbers as sputum absent patients did not submit sputum for comparison
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in HIV patients with direct drug susceptibility testing, it
is important to mention the role of GeneXpert as com-
pared to MODS. GeneXpert would also be a welcome al-
ternative to the current standard of care in Bolivia for
HIV patients. However, at the current time, without a
committed long-term external funding source, its cost
($10/cartridge and $17,000/machine) limits widespread
implementation in resource-limited settings like Bolivia
[13]. MODS ($3/test) remains a more cost-effective al-
ternative in these settings. Additionally, given MODS
performance in smear negative patients as demonstrated
in this study and others, and GeneXpert limitations in
this domain [14, 15], we would also recommend MODS
as a low cost alternative for GeneXpert for smear nega-
tive patients.
Our study provides data about sputum scarce HIV
patients with respiratory symptoms in a TB endemic area.
Despite minimal sputum production, the prevalence of TB
in this population trended towards higher than the
sputum-productive subjects and the 60 day mortality rate
of those TB+ was greater in the sputum-scarce group than
the sputum productive patients.
Additionally, we examine the value of the string test as a
sample obtainment method for TB in sputum scarce or
absent patients. In our sputum-scarce group, the string
test detected over 80 % of TB cases, and was not signifi-
cantly different than the number of TB cases by induced
sputum. Importantly, in the 10 patients that could not
produce a sputum sample despite induction, the string
test detected 4 cases of TB that would have otherwise
been missed; thus 40 % of patients that could not produce
a sputum sample were diagnosed and received treatment
because of the string test. Our diagnostic yield is lower
than in previous studies [24], this may be due to lack of
neutralization before storage and delayed processing of
samples. Despite this, the string test provided an inexpen-
sive, minimally invasive alternative for diagnosis of TB in
sputum-scarce and sputum-absent patients without an as-
sociated biohazard risk. Given the above data, we suggest
that the string test be considered as an alternate sample
obtainment method used in conjunction with MODS in
HIV patients with little to no sputum production.
Of the patients with both induced and spontaneous
sputa (n = 24), although the difference of the results be-
tween the two groups were not statistically significant,
two patients that were negative for TB by spontaneous
sputum were TB+ by induced sputum. Although induc-
tion of sputum in the diagnosis of TB is historically
more common in the pediatric population [30, 31],
more recent studies evaluating the utility in adults in
HIV-endemic regions have come to differing conclu-
sions [32–35]. Small studies have promoted the use of
induction of sputum by demonstrating an increased
diagnostic yield when compared to spontaneous sputum
[32–34]; however, a randomized controlled trial of 418
patients in South Africa did not show a significant dif-
ference between the results of healthcare worker-
instructed versus induced sputum [35]. Furthermore, in-
duction of sputum requires additional equipment, poses
a biohazard risk, and is an increased cost to hospitals
(US$2.14 vs $7.88) [35].
Additionally, our study is the first in Bolivia to dem-
onstrate that MODS is superior to the current local
standards of tuberculosis diagnosis. We showed that a
laboratory with minimal prior experience with MODS is
able to produce results similar to that of centralized
MODS laboratories, as in Peru, where MODS is now the
standard of care [23].. Furthermore, the implementation
of MODS can be more simplified and affordable in the
future, with the recent development of MODS kits and
availability of inexpensive inverted microscopes [21–23].
Limitations of our study include our increased time to
positivity compared to prior studies in Peru [18, 19].
This increase may have been influenced by delay in pro-
cessing times of the samples, and the fact that samples
were checked less often (due to personnel availability),
rather than every day. Although most samples were cul-
tured within 4 days of collection (Median 3.5, IQR 1–6),
some were stored for up to 11 days, which may have af-
fected growth of culture. The diagnostic yield of the
string test in this study is lower than previous studies
[24]; it is important to note our lack of neutralization of
the sample before storage as well as delays in processing
samples may have decreased string test yield and is a
limitation of our study.
Our imperfect reference standard was an additional limi-
tation to optimally evaluate the diagnostic performance of
MODS. The performance of MODS would have been more
clearly defined if our standard included other sensitive diag-
nostic methods such as MGIT or GeneXpert rather than a
composite of all of the tests being evaluated. This was due
to logistical limitations and financial constraints. Although
the comparison of MODS to the standard solid culture
media for diagnosis of TB in Bolivia provides important
data for the community tested, the incorporation of Gen-
eXpert in our study would have been a valuable compari-
son, had it been a possibility.
Additionally, there is a gap in our data regarding the
mortality of the HIV patients that were negative for TB.
Regrettably we did not record the mortality data for all pa-
tients without TB during the time of the study, thus we
are not able to make a comparison in mortality between
the TB-positive and TB-negative patients.
In many parts of the world, HIV is no longer a death sen-
tence, but has become a manageable chronic disease due to
increased detection and wider availability of effective treat-
ments. The currently undertreated and highly lethal HIV-
TB co-infection is a barrier to this becoming a reality in
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many TB-endemic areas such as Bolivia. Implementation of
MODS, or if economically feasible, another rapid diagnostic
test such as GeneXpert, should become the standard for
diagnosis of TB in HIV populations in resource-scarce set-
tings. This would empower clinicians to treat patients with
effective antimicrobials at earlier time points, which would
lead to significant effects on both patient mortality and pub-
lic health through decreased transmission of this deadly
disease.
Conclusions
The high prevalence and mortality of TB-HIV co-infection
found in our study and others highlights the need for a
more rapid diagnostic test for TB that includes direct drug
susceptibility testing in HIV patients in Bolivia and in similar
resource-limited settings. MODS culture performs well in
this setting, and should be considered as a low cost alterna-
tive in HIV patients. In addition, a more effective approach
to symptomatic HIV patients with little or no sputum pro-
duction is needed; the string test could be a valuable diag-
nostic tool for this subset of patients.
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